

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM406945

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Teva Canada Limited/Teva Canada Limitee		11/21/2016	Corporation: CANADA
RECEIVING PARTY DATA			
Name:	Rhodes Pharmaceuticals L.P.		
Street Address:	498 Washington St		
City:	Coventry		
State/Country:	RHODE ISLAND		
Postal Code:	02816		
Entity Type:	Limited Partnership: DELAWARE		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Registration Number:	2721535	LOFIBRA	
Registration Number:	2878015	LOFIBRA	
CORRESPONDENCE DATA			
Fax Number:	4012629401		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Email:	James.Doyle@pharma.com		
Correspondent Name:	James Doyle		
Address Line 1:	498 Washington St		
Address Line 4:	Coventry, RHODE ISLAND 02816		
NAME OF SUBMITTER:	Christine M. Hlavka		
SIGNATURE:	/Christine M. Hlavka/		
DATE SIGNED:	11/29/2016		
Total Attachments: 3			
source=TRADEMARK ASSIGNMENT - Executed Copy#page1.tif			
source=TRADEMARK ASSIGNMENT - Executed Copy#page2.tif			
source=TRADEMARK ASSIGNMENT - Executed Copy#page3.tif			

OP \$65.00 2721535

TRADEMARK ASSIGNMENT

WHEREAS, Teva Canada Limited/Teva Canada Limitee, a corporation organized and existing under the laws of Canada, with a principal place of business located at 30 Novopharm Ct., Toronto, ON M1B 2K9, Canada (hereinafter referred to as "ASSIGNOR"), is the owner of the trademarks shown on the attached Schedule (hereinafter referred to as the "Marks");

WHEREAS Rhodes Pharmaceuticals L.P., a limited partnership organized and existing under the laws of Delaware, with a principal place of business located at 498 Washington Street, Coventry, Rhode Island 02816 (hereinafter referred to as "ASSIGNEE"), desires to acquire all right, title and interest of ASSIGNOR in, to and under the Marks; and

WHEREAS, the parties desire to formalize said assignment and record same in the United States Patent and Trademark Office and other registries as appropriate.

NOW, THEREFORE, in consideration of the sum of Ten Dollars (\$10.00) and other good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, ASSIGNOR hereby transfers and assigns to ASSIGNEE all right, title and interest of ASSIGNOR in, to and under the Marks, together with the goodwill associated therewith and the registration thereof;


ASSIGNOR does also hereby sell, assign, transfer and set over unto ASSIGNEE, its successors, legal representatives and assigns all claims for damages by reason of infringement of the Marks, the right to sue for and collect the same for its own use and enjoyment and for the use and enjoyment of its successors, assigns or other legal representative;

ASSIGNOR further authorizes the United States Patent and Trademark Office to record said assignment so as to show ownership of the Marks in the name of Rhodes Pharmaceuticals L.P., the Assignee; and

ASSIGNOR further agrees to execute such further documents as may reasonably be required to record ASSIGNEE as the owner of the Marks and registrations herein assigned.

IN WITNESS WHEREOF, this instrument has been executed this 21st day of
November, 2016.

EXECUTED by authority for and on behalf of
Teva Canada Limited/Teva Canada Limitee

By: 
Name: Suzanne Grand
Title: Sr. Director Finance

By: 
Name: Doug Sommerville
Title: SVP & General Manager

LEGAL AFFAIRS
75

Assignment Schedule – UNITED STATES

Trademark	Registration No.	Registration Date:
LOFIBRA	2,721,535	June 3, 2003
LOFIBRA	2,878,015	August 24, 2004